{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:03:43Z","timestamp":1761581023833,"version":"3.44.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ucl.2012.07.011","type":"journal-article","created":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T01:19:01Z","timestamp":1347412741000},"page":"561-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Advanced Clinical States in Prostate Cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Heather H.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ucl.2012.07.011_bib1","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2012.07.011_bib2","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group","volume":"17","author":"Bubley","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.011_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","article-title":"The androgen axis in recurrent prostate cancer","volume":"10","author":"Mohler","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ucl.2012.07.011_bib4","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","article-title":"Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer","volume":"11","author":"Titus","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ucl.2012.07.011_bib5","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2012.07.011_bib6","article-title":"Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study","volume":"30","author":"Scher","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9724","key":"10.1016\/j.ucl.2012.07.011_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ucl.2012.07.011_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.011_bib9","first-page":"540","volume":"177","author":"Cookson","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"6 Pt 1","key":"10.1016\/j.ucl.2012.07.011_bib10","first-page":"2255","article-title":"Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (CAPSURE)","volume":"171","author":"Greene","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.011_bib11","first-page":"1146","article-title":"Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?","volume":"165","author":"Amling","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"24","key":"10.1016\/j.ucl.2012.07.011_bib12","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer\u00a0after radical prostatectomy: a proposal for a standardized definition","volume":"24","author":"Stephenson","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.011_bib13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ucl.2012.07.011_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0360-3016(00)00577-0","article-title":"Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials","volume":"47","author":"Roach","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.ucl.2012.07.011_bib15","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.011_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"issue":"5 Pt 2","key":"10.1016\/j.ucl.2012.07.011_bib17","first-page":"S42","article-title":"Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy","volume":"172","author":"D'Amico","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"24","key":"10.1016\/j.ucl.2012.07.011_bib18","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ucl.2012.07.011_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.011_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/aja.2011.108","article-title":"Quality of\u00a0life issues in men undergoing androgen deprivation therapy: a review","volume":"14","author":"Casey","year":"2012","journal-title":"Asian J Androl"},{"issue":"10","key":"10.1016\/j.ucl.2012.07.011_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nrurol.2010.141","article-title":"Intermittent androgen suppression for prostate cancer","volume":"7","author":"Buchan","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"Suppl 7","key":"10.1016\/j.ucl.2012.07.011_bib22","article-title":"A\u00a0phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7\/SWOG JPR.7\/CTSU JPR.7\/UK Intercontinental Trial CRUKE\/01\/013","volume":"29","author":"Klotz","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.011_bib23","article-title":"A\u00a0phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7\/SWOG JPR.7\/CTSU JPR.7\/ UK Intercontinental Trial CRUKE\/01\/013)","volume":"29","author":"Crook","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.011_bib24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ucl.2012.07.011_bib25","first-page":"2239","article-title":"Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer","volume":"186","author":"Smith","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"15","key":"10.1016\/j.ucl.2012.07.011_bib26","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2011.38.3745","article-title":"Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer","volume":"30","author":"Yu","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.ucl.2012.07.011_bib27","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1200\/JCO.2009.25.1330","article-title":"Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation","volume":"28","author":"Yu","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2012.07.011_bib28","volume":"30","author":"Yu","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.ucl.2012.07.011_bib29","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1158\/1078-0432.CCR-10-3223","article-title":"Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer","volume":"17","author":"Beer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.011_bib30","unstructured":"Dendreon. Sequencing of Sipuleucel-T and ADT in\u00a0Menwith Non-metastatic Prostate Cancer. Available at: ClinicalTrials.gov(NCT01431391). Accessed August 15, 2012."},{"issue":"39","key":"10.1016\/j.ucl.2012.07.011_bib31","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.1073\/pnas.0908908106","article-title":"Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6","volume":"106","author":"Gibbs","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.011_bib32","article-title":"Maximal androgen blockade for advanced prostate cancer","author":"Schmitt","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.011_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0090-4295(00)01086-4","article-title":"Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review","volume":"57","author":"Schmitt","year":"2001","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2012.07.011_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.10647","article-title":"Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma","volume":"95","author":"Samson","year":"2002","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.011_bib35","first-page":"30","article-title":"Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial","author":"Hussain","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.011_bib36","article-title":"Preliminary quality-of-life outcomes for SWOG-9346: intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)\u2014Phase III","volume":"30","author":"Moinpour","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.ucl.2012.07.011_bib37","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.ucl.2012.07.011_bib38","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.011_bib39","unstructured":"Southwest Oncology Group. Bicalutamide and goserelin or leuprolide acetate with or without cixutumumab in treating patients with newly diagnosed metastatic prostate cancer. Available at: ClinicalTrials.gov\/ct2\/show\/NCT01120236. Accessed August 15, 2012."},{"issue":"18 Pt 2","key":"10.1016\/j.ucl.2012.07.011_bib40","doi-asserted-by":"crossref","first-page":"5549s","DOI":"10.1158\/1078-0432.CCR-07-1109","article-title":"IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor","volume":"13","author":"Rowinsky","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.011_bib41","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1158\/1078-0432.CCR-04-1586","article-title":"In\u00a0vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors","volume":"11","author":"Wu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.011_bib42","unstructured":"Eastern Cooperative Oncology Group. Androgen ablation therapy with or without chemotherapy in treating patients with metastatic prostate cancer. Available at: ClinicalTrials.gov\/ct2\/show\/NCT00309985. Accessed August 15, 2012."},{"issue":"13","key":"10.1016\/j.ucl.2012.07.011_bib43","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2012.07.011_bib44","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cncr.25762","article-title":"Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer","volume":"117","author":"Smith","year":"2011","journal-title":"Cancer"},{"issue":"9810","key":"10.1016\/j.ucl.2012.07.011_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.011_bib46","first-page":"103","article-title":"Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer","volume":"188","author":"Yu","year":"2012","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2012.07.011_bib47","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.ucl.2012.07.011_bib48","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A\u00a0contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.011_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","article-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ucl.2012.07.011_bib50","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1002\/cncr.25982","article-title":"The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy","volume":"117","author":"Sonpavde","year":"2011","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.ucl.2012.07.011_bib51","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO.2008.18.9159","article-title":"Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer","volume":"27","author":"Halabi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2012.07.011_bib52","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2012.07.011_bib53","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/1078-0432.CCR-10-2650","article-title":"Circulating tumor cells as biomarkers in prostate cancer","volume":"17","author":"Danila","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ucl.2012.07.011_bib54","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.ucl.2012.07.011_bib55","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ucl.2012.07.011_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","article-title":"Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data","volume":"10","author":"Scher","year":"2009","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.ucl.2012.07.011_bib57","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.011_bib58","unstructured":"Southwest Oncology Group. Combination therapy in\u00a0treating patients with advanced prostate cancer that has not responded to hormone therapy. Available at: ClinicalTrials.gov\/ct2\/show\/NCT00004001. Accessed August 15, 2012."},{"issue":"9747","key":"10.1016\/j.ucl.2012.07.011_bib59","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ucl.2012.07.011_bib60","unstructured":"Sanofi-Aventis. Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA). Available at: ClinicalTrials.gov\/ct2\/show\/NCT01308567. Accessed August 15, 2012."},{"issue":"5","key":"10.1016\/j.ucl.2012.07.011_bib61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ucl.2012.07.011_bib62","unstructured":"OHSU Knight Cancer Institute. Ipilimumab in combination with androgen suppression therapy in treating patients with metastatic hormone-resistant prostate cancer. Available at: Clinicaltrials.gov\/ct2\/show\/NCT01498978. Accessed August 15, 2012."},{"issue":"7","key":"10.1016\/j.ucl.2012.07.011_bib63","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.011_bib64","unstructured":"BN ImmunoTherapeutics. A phase 3 efficacy study of a recombinant vaccinia virus vaccine to treat metastatic prostate cancer (prospect). Available at: ClinicalTrials.gov\/ct2\/show\/NCT01322490. Accessed August 15, 2012."},{"key":"10.1016\/j.ucl.2012.07.011_bib65","unstructured":"Squibb B-M. Phase 3 study of immunotherapy to treat advanced prostate cancer. Available at: ClinicalTrials.gov\/ct2\/show\/NCT01057810. Accessed August 15, 2012."},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.011_bib66","article-title":"Interim analysis results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy naive patients with metastatic castration-resistant prostate cancer","author":"Ryan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.011_bib67","article-title":"Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor","author":"de Bono","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.011_bib68","unstructured":"Medivation, Inc. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). Available at: ClinicalTrials.gov\/ct2\/show\/NCT01212991. Accessed August 15, 2012."},{"issue":"6","key":"10.1016\/j.ucl.2012.07.011_bib69","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ucl.2012.07.011_bib70","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9768","key":"10.1016\/j.ucl.2012.07.011_bib71","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"20 Pt 2","key":"10.1016\/j.ucl.2012.07.011_bib72","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2012.07.011_bib73","article-title":"Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases","author":"Parker","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.011_bib74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cncr.26204","article-title":"Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study","volume":"118","author":"Araujo","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2012.07.011_bib75","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":"Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"issue":"23","key":"10.1016\/j.ucl.2012.07.011_bib76","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2012.07.011_bib77","unstructured":"Squibb BM. Randomized study comparing docetaxel plus dasatinib to docetaxel plus placebo in castration-resistant prostate cancer (READY). Available at: ClinicalTrials.gov\/ct2\/show\/NCT00744497. Accessed August 15, 2012."},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.011_bib78","article-title":"Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial","volume":"29","author":"Hussain","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.011_bib79","unstructured":"Exelixis. Study of cabozantinib (XL184) versus prednisone in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone or MDV3100 (COMET-1). Available at: ClinicalTrials.gov\/ct2\/show\/NCT01605227. Accessed August 15, 2012."},{"key":"10.1016\/j.ucl.2012.07.011_bib80","unstructured":"Exelixis. Study of cabozantinib (XL184) versus mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer (COMET-2). Available at: ClinicalTrials.gov\/ct2\/show\/NCT01522443. Accessed August 15, 2012."},{"key":"10.1016\/j.ucl.2012.07.011_bib81","unstructured":"Teva Pharmaceutical Industries. Comparison of docetaxel\/prednisone to docetaxel\/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY). Available at: ClinicalTrials.gov\/ct2\/show\/NCT01188187. Accessed August 15, 2012."},{"issue":"27","key":"10.1016\/j.ucl.2012.07.011_bib82","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.26.8771","article-title":"Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer","volume":"28","author":"Chi","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2012.07.011_bib83","article-title":"A\u00a0randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"30","author":"Chi","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.ucl.2012.07.011_bib84","article-title":"Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): safety and efficacy analysis including subgroups","volume":"29","author":"Armstrong","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.011_bib85","article-title":"Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: results of long-term follow-up of a randomized phase II placebo-controlled trial","volume":"30","author":"Armstrong","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ucl.2012.07.011_bib86","unstructured":"Active Biotech AB. A study of tasquinimod in men with metastatic castrate resistant prostate cancer. Available at: ClinicalTrials.gov\/ct2\/show\/NCT01234311. Accessed August 15, 2012."},{"key":"10.1016\/j.ucl.2012.07.011_bib87","article-title":"Application of the functional diffucsion map (fDM) to assess treatment response in metastatic prostate cancer (PCa)","author":"Bradley","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2012.07.011_bib88","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/RLU.0b013e318208f140","article-title":"C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy","volume":"36","author":"Yu","year":"2011","journal-title":"Clin Nucl Med"},{"issue":"8","key":"10.1016\/j.ucl.2012.07.011_bib89","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.ejrad.2012.04.027","article-title":"Role of (11)C-choline PET\/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy","volume":"81","author":"Fuccio","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ucl.2012.07.011_bib90","doi-asserted-by":"crossref","DOI":"10.1111\/j.1464-410X.2012.11123.x","article-title":"Combined (18) F-fluorocholine and (18) F-fluoride positron emission tomography\/computed tomography imaging for staging of high-risk prostate cancer","author":"Kjolhede","year":"2012","journal-title":"BJU Int"},{"issue":"Suppl","key":"10.1016\/j.ucl.2012.07.011_bib91","article-title":"18F-16beta-fluoro-5alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC)","volume":"30","author":"Autio","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2012.07.011_bib92","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2967\/jnumed.109.073908","article-title":"Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications","volume":"51","author":"Kwee","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.ucl.2012.07.011_bib93","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.semnuclmed.2004.06.004","article-title":"Positron emission tomography for prostate, bladder, and renal cancer","volume":"34","author":"Schoder","year":"2004","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.ucl.2012.07.011_bib94","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline","volume":"52","author":"Jadvar","year":"2011","journal-title":"J\u00a0Nucl Med"},{"issue":"127","key":"10.1016\/j.ucl.2012.07.011_bib95","doi-asserted-by":"crossref","first-page":"127rv3","DOI":"10.1126\/scitranslmed.3003180","article-title":"Beyond PSA: the next generation of prostate cancer biomarkers","volume":"4","author":"Prensner","year":"2012","journal-title":"Sci Transl Med"},{"issue":"7333","key":"10.1016\/j.ucl.2012.07.011_bib96","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"issue":"7153","key":"10.1016\/j.ucl.2012.07.011_bib97","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature06024","article-title":"Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer","volume":"448","author":"Tomlins","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ucl.2012.07.011_bib98","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/modpathol.2008.96","article-title":"Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome","volume":"21","author":"Yoshimoto","year":"2008","journal-title":"Mod Pathol"},{"issue":"94","key":"10.1016\/j.ucl.2012.07.011_bib99","doi-asserted-by":"crossref","first-page":"94ra72","DOI":"10.1126\/scitranslmed.3001970","article-title":"Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA","volume":"3","author":"Tomlins","year":"2011","journal-title":"Sci Transl Med"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014312000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014312000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:25:30Z","timestamp":1758806730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014312000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0094014312000596"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2012.07.011","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced Clinical States in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2012.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}